Spironolactone

"Spironolactone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)

Descriptor ID	D013148
MeSH Number(s)	D02.540.679 D04.210.500.745.745.855
Concept/Terms	Spironolactone Spironolactone Spirolactone Veroshpiron Verospirone Spiractin Spiractin Spirobeta Spirobeta Spirogamma Spirogamma Spirolang Spirolang Spirono-Isis Spirono-Isis Spirono Isis Spironone Spironone Spirospare Spirospare Aldactone Aldactone Verospiron Verospiron Aldactone A Aldactone A Aquareduct Aquareduct Duraspiron Duraspiron Espironolactona Alter Espironolactona Alter Espironolactona Mundogen Espironolactona Mundogen Flumach Flumach Frumikal Frumikal Jenaspiron Jenaspiron Novo-Spiroton Novo-Spiroton Novo Spiroton NovoSpiroton Practon Practon SC-9420 SC-9420 SC 9420 SC9420 Spiro L.U.T. Spiro L.U.T. Spiro Von Ct Spiro Von Ct Ct, Spiro Von Von Ct, Spiro

Below are MeSH descriptors whose meaning is more general than "Spironolactone".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Lactones [D02.540]
Spironolactone [D02.540.679]
Polycyclic Compounds [D04]
Fused-Ring Compounds [D04.210]
Steroids [D04.210.500]
Pregnanes [D04.210.500.745]
Pregnenes [D04.210.500.745.745]
Spironolactone [D04.210.500.745.745.855]

Below are MeSH descriptors whose meaning is related to "Spironolactone".

Below are MeSH descriptors whose meaning is more specific than "Spironolactone".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Spironolactone" by people in this website by year, and whether "Spironolactone" was a major or minor topic of these publications.

Bar chart showing 8 publications over 7 distinct years, with a maximum of 2 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	1	1	2
2007	1	0	1
2012	1	0	1
2015	1	0	1
2018	1	0	1
2022	1	0	1
2024	1	0	1

Below are the most recent publications written about "Spironolactone" by people in Profiles.

Natov PS, Ivey-Miranda JB, Cox ZL, Rao VS, Butler J, Konstam MA, Kiernan MS, Kapur NK, Testani JM. Increased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does not Enhance Decongestion. J Card Fail. 2024 Nov; 30(11):1522-1526.

View in: PubMed
Petty HJ, Barrett JE, Kosmowski EG, Amos DS, Ryan SM, Jones LD, Lassiter CS. Spironolactone affects cardiovascular and craniofacial development in zebrafish embryos (Danio rerio). Environ Toxicol Pharmacol. 2022 May; 92:103848.

View in: PubMed
Maron MS, Chan RH, Kapur NK, Jaffe IZ, McGraw AP, Kerur R, Maron BJ, Udelson JE. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018 07; 131(7):837-841.

View in: PubMed
Arnold AC, Okamoto LE, Gamboa A, Black BK, Raj SR, Elijovich F, Robertson D, Shibao CA, Biaggioni I. Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure. Hypertension. 2016 Feb; 67(2):424-9.

View in: PubMed
Hassan M, Qureshi W, Sroujieh LS, Albashaireh D, BouMalham S, Liroff M, Amjad W, Khalid F, Hadid H, Alirhayim Z. Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease. J Renin Angiotensin Aldosterone Syst. 2014 Sep; 15(3):278-85.

View in: PubMed
Kiernan MS, Konstam MA. Moderate renal insufficiency does not attenuate the clinical benefit of aldosterone antagonists in heart failure. J Am Coll Cardiol. 2012 Nov 13; 60(20):2090-1.

View in: PubMed
Raebel MA, McClure DL, Chan KA, Simon SR, Feldstein AC, Lafata JE, Andrade SE, Gunter MJ, Nelson WW, Roblin D, Platt R. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia? Ann Pharmacother. 2007 Feb; 41(2):193-200.

View in: PubMed
Khurshid KA, Weaver ME. Conn's syndrome presenting as depression. Am J Psychiatry. 2005 Jun; 162(6):1226.

View in: PubMed
Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation. 2005 Mar 08; 111(9):1106-13.

View in: PubMed
Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003 Oct 14; 108(15):1831-8.

View in: PubMed

People

Explore

Similar Concepts

Top Journals